

CELGENE CORP /DE/
Form 425
January 03, 2019

Client Id: 77 Filed by Bristol-Myers Squibb Company Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Celgene Corporation Commission File No.: 001-34912 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call EVENT DATE/TIME: JANUARY 03, 2019 / 1:00PM GMT THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. Filed by Bristol-Myers Squibb Company Pursuant to Rule 425 of the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Celgene Corporation Commission File No.: 001-34912 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call EVENT DATE/TIME: JANUARY 03, 2019 / 1:00PM GMT

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call CORPORATE PARTICIPANTS Charles A. Bancroft Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO Giovanni Caforio Bristol-Myers Squibb Company - Chairman of the Board & CEO John E. Elicker Bristol-Myers Squibb Company - SVP of Corporate Affairs & IR Mark J. Alles Celgene Corporation - Chairman & CEO S. J. Rupert Vessey Celgene Corporation - President of Research & Early Development Thomas J. Lynch Bristol-Myers Squibb Company - Executive VP of R&D & Chief Scientific Officer CONFERENCE CALL PARTICIPANTS Alex Arfaei BMO Capital Markets Equity Research - Pharmaceuticals Analyst Christopher Thomas Schott JP Morgan Chase & Co, Research Division - Senior Analyst David Reed Risinger Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst Geoffrey Christopher Meacham Barclays Bank PLC, Research Division - MD & Senior Research Analyst Geoffrey Craig Porges Leerink Partners LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst Jason Matthew Gerberry BofA Merrill Lynch, Research Division - MD in US Equity Research John Thomas Boris SunTrust Robinson Humphrey, Inc., Research Division - MD Seamus Christopher Fernandez Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals Stephen Michael Scala Cowen and Company, LLC, Research Division - MD and Senior Research Analyst Timothy Minton Anderson Wolfe Research, LLC - MD of Equity Research PRESENTATION Operator Good day, everyone. Welcome to today's conference and webcast to discuss the announcement. Today's call is being recorded. At this time, I would like to turn the call over to John Elicker, Senior Vice President, Investor Relations and Corporate Affairs. Please go ahead. John E. Elicker - Bristol-Myers Squibb Company - SVP of Corporate Affairs & IR Thank you, and good morning, everybody, and thanks for joining our call today to discuss the combination of Bristol-Myers Squibb and Celgene. Joining me today are Giovanni Caforio, our Chairman and CEO; along with Charlie Bancroft, our CFO; as well as Mark Alles, Chairman and CEO of Celgene. Giovanni, Charlie and Mark will have prepared remarks. And then joining us for Q&A will be Tom Lynch, our Chief Scientific Officer; Chris Boerner, our Chief Commercial Officer; and Rupert Vessey, President, Research and Early Development at Celgene. As a reminder, the call is being recorded and the press release and slide presentation regarding today's news are available on our website of both Bristol-Myers Squibb and Celgene. I'll refer you to Slides 2 and 3 of the presentation for legal disclosures, and I will turn it over to Giovanni. 2 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, John. Good morning, everyone. This is a historic day for both Bristol-Myers Squibb and Celgene. I am truly excited to be announcing the creation of a leading biopharma company. There are many compelling benefits to this transaction, and we've got a lot to cover today. And we are announcing this news with strong momentum in our current business, as you can see from the EPS guidance we issued this morning. Let's turn to Slide 5, which is a slide that many of you are familiar with. As you know, at Bristol-Myers Squibb, for more than 10 years now, we've been executing a consistent strategy that has served us well, enabled significant earnings growth and positioned us as a leading biopharma company. Our strategy is centered on combining the innovation and agility of biotech and the scale and flexibility of traditional pharma. It's also been focused on key therapeutic areas with high unmet medical need and a strong cash flow foundation to help patients in their fight against serious diseases. Today, we have announced the transaction that takes us to the next chapter as a company, and it does so in a way that is fully aligned with this strategic foundation. Together with Celgene and leveraging the power of the combined assets, people and technologies, we will build on, extend and strengthen this foundation, positioning the company for long-term sustainable growth. We will broaden our market portfolio, augment and diversify our pipeline and maintain the speed and agility that is central to our approach. Moving to Slide 6, you can really see the power of this combination. Let me walk you through some of the key features of the company we are creating, starting with the market products portfolio. We are creating the #1 oncology franchise, with leading positions in both solid tumors, led by Opdivo and Yervoy, and hematologic malignancies, with Revlimid and Pomalyst. The combined portfolio also creates a top 5 immunology and inflammation franchise, led by Ocrencia and Otezla. We will maintain our position as the #1 cardiovascular franchise, led by Eliquis. We will have 9 products with more than \$1 billion in annual sales and significant potential for growth in these areas. Complementing this leading franchise of in-line products, the combined company will have an industry-leading late-stage and early-stage pipeline. Looking to the late-stage pipeline first. We expect 6 near-term product launches over the next 12 to 24 months, representing more than \$15 billion in revenue potential. This is in addition to a significant number of lifecycle readouts, most of which are in our I/O portfolio. The combined company will also have a portfolio that is well positioned over the longer term, with a robust early-stage pipeline across our disease areas. We are excited about this early-stage assets, and I will highlight some of them in a few minutes. Importantly, all of these will be underpinned by cutting-edge technologies and discovery platforms that will enable us to accelerate new medicines for patients. Our expertise in small molecules and biologics will be complemented by Celgene's expertise and their discovery platforms in protein homeostasis, cell therapy and more. Together, we will have expanded internal capabilities and strong external partnerships that will provide access to additional modalities. Moving on to Slide 7. You will have seen the terms of the agreement in the press release, so I'm not going to spend time on those here. What I like to highlight is that this transaction is financially compelling on day 1. We will deliver strong returns with immediate EPS accretion. Charlie will provide more details later in the call. Now moving to Slide 8. Let me tell you how I think about this opportunity and how it is aligned to our business development priorities.

3 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call We've always said that when we look at BD, it must be strategically aligned to our therapeutic areas of focus. It must bring compelling science, with the potential for transformational medicines. And importantly, it must create value for shareholders. So when I look at this transaction, I believe it is clear we have met all of our criteria. First, there is great therapeutic [fit] across both companies in oncology and immunology and inflammation. Second, when you look at the pipeline and scientific capabilities of Celgene, we see tremendous opportunities for transformational medicines. Finally, we've spent a lot of time analyzing the opportunity, and I am confident we are creating value for Bristol-Myers Squibb shareholders. I am excited about what this means for the company. And I'll now turn it over to Mark. Mark J. Alles - Celgene Corporation - Chairman & CEO Thanks, Giovanni, and good morning, everyone. I'm excited to join Giovanni and his leadership team today to announce the combination of our industry-leading companies. Bristol-Myers Squibb and Celgene are 2 innovation-focused companies coming together to build an even stronger company with one mission: to discover, develop and deliver the most innovative medicines to patients with unmet needs across the continuum of care. For Celgene's shareholders, this cash and stock transaction recognizes and unlocks significant value by delivering immediate and substantial cash value and providing meaningful participation in the combined company's future, owning approximately 31% of the company after closing. Celgene's shareholders also benefit from an additional cash via dividends and the potential CVR payment. The strategic vision of this transaction is obvious and compelling: it significantly enhances our strong global leadership in oncology and vaults our inflammation and immunology business into the global top tier. Together with Bristol-Myers Squibb, we will have the financial strength to accelerate our research and development engine for sustainable long-term growth. Additionally, the combined company will continue its investment with our extensive portfolio of research partners. In short, the sum of the parts of each company has the potential to become the preeminent global biopharmaceutical company. Before I turn the call back to Giovanni, I need to thank my Celgene colleagues for what they have built, what they are doing and will continue to do for many years to come. More than anything else, the combination of Bristol-Myers Squibb and Celgene will build on the skills, commitment and passion of our people who are dedicated to changing human health. I am grateful to be part of such an incredible group and look forward to helping Giovanni and all my colleagues deliver on the promise and potential of the new Bristol-Myers Squibb. Thank you, and I'm pleased to turn the call back to Giovanni. Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, Mark. Let me now tell you how I am thinking of the new company and its different components, starting with our commercialized portfolio as a first value driver. On Slide 10, you'll see that, together, we will have leading franchises in our 4 core therapeutic areas in large and growing markets. The combined portfolio not only diversifies our revenue streams, but also provides a platform for sustained leadership. Moving to Slide 11. 4 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call As I've said earlier, we are creating a leading oncology company by complementing the strengths of the solid tumor business from Bristol-Myers Squibb with Celgene's leading hematology portfolio. Taking a look at Slide 12, you can see the success we've had at establishing our I/O portfolio as a key pillar in the treatment of solid tumors. We have driven strong commercial execution in I/O, with \$7.5 billion in annualized sales, more than 400 approvals for Opdivo and 17 U.S. indications in 4 years following the launch. Our I/O business continues to perform well in a highly competitive market, and we have strong commercial momentum with leading shares in core indications. Looking to the future, we are encouraged by the opportunities we have moving forward, including more than 20 near-term registrational readouts. We are also excited by the potential to move I/O into early disease settings, develop PD-1 combinations with existing standards of care and address emerging I/O refractory second line. All together, given the strength of our business and the opportunities that we see, I believe that we will continue to have a strong and leading I/O business into the future. Importantly, we will ensure that our commercial and R&D teams remain focused on delivering the value of this business. Looking at Slide 13. Clearly, the multiple myeloma market today has been transformed by the medicines Celgene has developed to benefit patients with this disease. Given the foundation established by Revlimid and Pomalyst, we see the market evolving from the imid paradigm to one that includes new targets and modalities, such as BCMA, CELMoD and CAR T. And we are very encouraged by the breadth of assets and modalities in Celgene's hematology pipeline. There are also 4 near-term assets with the potential to launch in hematology in the next 12 to 24 months. All these together strengthens our belief that this company is best positioned for long-term leadership in hematology. Let's turn to Slide 14. One thing that may be on your mind is how we evaluated Revlimid and the IP situation. This is actually a slide from Celgene's presentation at the ASH conference about a month ago. We recognize that there is debate about the IP status of Revlimid. And as you would expect, we conducted extensive due diligence on Revlimid. We agree with how Celgene have described the IP situation. As we've looked at Revlimid, we have taken a more conservative view on sales that is in consensus models. As you would expect, we evaluated a range of potential outcomes, and we feel very good about the valuation. As you can see from Slide 15, moving beyond oncology, I am excited about the opportunity we have in immunology and inflammation. We have a good foundation with Otezla and Orencia and 2 near term potential launches, with ozanimod and TYK2, which we are very excited about. In addition, we have an expanded portfolio of early-stage assets that provide increased scale to compete in this important disease area. Moving to Slide 16. The second key value driver of this transaction is the fact that the combined company will have 6 potential product launches in the next 12 to 24 months, with significant revenue potential. We will have 2 potential launches in immunology and inflammation, TYK2 and ozanimod, and as you see on the slide, 4 launches in hematology. These launches leverage the combined commercial capabilities across oncology and immunology and inflammation and will broaden Bristol-Myers Squibb market position with innovative and differentiated products. We believe these assets have the potential to generate greater than \$15 billion in peak sales, while adding scale and breadth to our immunology and oncology franchises as well as being the first step to the next stage in hematology leadership.

5 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call

On Slide 17, you can see our pipeline is broad and deep. It's well diversified across our therapeutic areas and stages of development. This pipeline builds a sustainable platform for growth beyond the near-term product launches. It represents an important third driver of value in this transaction. We've already talked about the late-stage portfolio. Now going a little deeper on Slide 18, on the pipeline, the assets we're highlighting are ones to watch over the next several years as they advance through the next stages of development. As you see on Slide 19, and we have touched on this already, success in this industry is based on innovation underpinned by great science. And clearly, BMS and Celgene have successfully demonstrated this over the last 10 years, with a profound impact on patient lives. I am really excited to bring these 2 organizations together that will create the leading science and innovation-based biopharmaceutical company. Now I'll turn it over to Charlie to provide more detail on the financial benefits. Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO Thanks, Giovanni. Good morning, everyone. Turning to Slide 20. As Giovanni explained, we also view this as a very compelling transaction from a financial perspective. In terms of consideration, as you've all seen in our press release, each Celgene shareholder will receive \$50 in cash, 1 BMS share and 1 CVR. Let me briefly walk you through some of the details on the CVR. We structured the CVR to align the interest of Bristol-Myers Squibb and Celgene shareholders for a scenario where there are multiple successes from the near-term portfolio. The CVR will be paid only if all 3 products are approved in the appropriate time, which we view as a clear value-creating scenario for shareholders of both companies. On the next slide, Page 21, I'll walk you through some of the details of the financial benefits of this transaction. We expect the transaction will bring significant financial benefits to shareholders of both companies from day 1. We believe we'll generate returns in excess of both companies' cost of capital and deliver more than 40% accretion in the first full year. From a balance sheet perspective, we will remain in a very strong position. We project substantial free cash flow in excess of \$45 billion in the first 3 years, which provides us with the flexibility to delever and maintain strong investment grade credit rating. It also supports our continued commitment to our dividend, as evidenced by our announcement a month ago on our 10th consecutive annual increase, which will benefit shareholders from both companies. Finally, you'll note that we've announced an intent to execute a \$5 billion ASR upon closing the transaction. Let me now touch on synergies, which you can see on Page 22, which we view as an important fourth value driver. The synergies of \$2.5 billion are an important additional source of value. We anticipate that the savings will come from across the P&L, including SG&A, R&D and manufacturing. We estimate the synergies will constitute roughly 13% of pro forma combined spend, which is in line with previous transactions of this size and scope. Critical of how we think about synergies will be the following guiding principles to ensure we retain talent, protect key value drivers and leverage the enhanced scale of the new company. Turning to Slide 23, you'll see some of the financing details. As you've seen in the press release, this transaction is not contingent on financing, as we've already secured a bridge facility. With respect to the outstanding Celgene debt, it will be pari passu to existing BMS debt. Moving to Slide 24. We are confident that we have a clear roadmap ahead to complete this transaction. We are expecting to close in the third quarter of this year, subject to shareholder votes from both companies, receipt of regulatory approvals and other customary closing conditions. With that, I'll hand it back to Giovanni.

6 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, Charlie. To conclude our remarks, I want to highlight how excited I am about the opportunity we have to create a premier innovative biopharma company. We will be building on the strong patient focus that is core to both companies. For employees of both companies, we believe this combination will provide additional growth and advancement opportunities over the years to come. I am incredibly proud of the team we've built at Bristol-Myers Squibb, and I look forward to welcoming the talented members of the Celgene team. With that, I'll open up for Q&A. Operator? John E. Elicker - Bristol-Myers Squibb Company - SVP of Corporate Affairs & IR Yes. Thank you all. I think we're ready to go to the Q&A, and just to remind everybody, Giovanni, Mark and Charlie are obviously here for your questions, but Tom, Rupert and Chris are here as well. Nicole? QUESTIONS AND ANSWERS Operator (Operator Instructions) We'll take our first question from Chris Schott with JPMorgan. Christopher Thomas Schott - JP Morgan Chase & Co, Research Division - Senior Analyst I guess, my question is a bigger picture one to start with here. Historically, large M&A in the group has had a very mixed track record. Just help us understand why we should think about this differently as what other has got wrong and how you think you can avoid those challenges? And then as a follow-on to that, I just was interested in the timing of the transaction. I think about the Bristol side of the business, it does seem like you have a number of important Opdivo readouts coming over the next year or so, so just what led you to think about doing a deal now versus waiting for some of those readouts as we think about kind of if you're using stock, et cetera? Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, Chris. Let me start by discussing the value of this transaction. And from my perspective, this is a truly unique combination of 2 very complementary companies. When you look at the product portfolio and the pipeline, there is extraordinary complementarity. The companies are active in areas of science, which are the same: oncology, immunology and inflammation. At the same time, they're complementary because we have a presence in solid tumors, Celgene is a leader in hematology. Together, we build a strong immuno science franchise. Again, as I said, the complementarity of these 2 companies is quite unique. And in fact, because of that, we've been discussing the potential for this combination for quite some time. And when you think about the value drivers, there are really 4 drivers of value here. The first one is the scale of the commercial portfolio that enables us to bring together leading franchises in the fastest-growing areas of the pharmaceutical market. Obviously, the second and really important value driver is that we have a number of short-term launches happening. In the next 12 to 24 months, 6 launches, which will deliver the value of this combination in the short term to shareholders. The third value driver is the synergies, which we are focused on obtaining. And then, obviously, the fourth value driver is the early and mid-stage pipeline, which is extremely broad and deep across multiple modalities. So when you look at it all together, it is a very unique combination of 2 companies that bring -- that bring together a very complementary set of opportunities from all points of view. 7 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call In terms of why now, where we are as Bristol-Myers Squibb, we are coming out of a very strong 2018. Today, we issued guidance for '19. From anEPS perspective, that clearly confirms the momentum in our business. Given the number of short-term launches and growth opportunities, we believe this is the right time. And from my perspective, I feel comfortable that, on the solid tumor side, we will be able to keep our teams focused on delivering on the growth opportunities that we have and the multiple catalysts that we have with 20 registrational readouts. We've been very thoughtful and very careful with respect to how we've structured the deal. And I like to ask Charlie to give you his perspective about that. Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO Thanks, Chris, and good morning. So we thought very carefully about using stock in this transaction. And I would say, overall, this is a very compelling acquisition from a value-creation perspective, including using our stock. And we really used equity for 2 reasons: one, we believe it's important to maintain the flexibility that comes from continuing to have a very strong credit rating; and two, it also allows for Celgene shareholders to continue as owners of the combined business as they wanted to participate in the potential upside of the combined company. So regarding how we've chosen to finance the transaction, there were a number of attracting sort of factors. One was cash on hand, but also the significant debt complex that we would have post-acquisition. But we do have -- we'd start a very strong balance sheet because we were able to delever pretty quickly. And it's also to point out that, as I said in my comments, we're also going to execute a \$5 billion ASR post-acquisition that will partially offset the dilution to existing BMS shareholders. Operator We'll take our next question from Geoff Meacham with Barclays. Geoffrey Christopher Meacham - Barclays Bank PLC, Research Division - MD & Senior Research Analyst Giovanni, I wanted to ask you where the cell therapy platform fits in your strategic priorities. It's not been a focus area for Bristol, previously. And along these lines, obviously, you have the value drivers of JCAR and 2121, which were very important to Celgene. How do you consider these in the valuation of the deal and then how do you look at the potential for solid tumors down the road with respect to the cell therapy platform? Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Yes, Geoff. Let me just start very quickly, and then Tom and Rupert will add their perspective. I am very excited with the opportunity to enter the field of cell therapy with the leading franchise that Celgene has built very thoughtfully over the last few years. When you think about our presence in oncology, we have a number of really exciting platforms. And by adding cell therapy now, we have significantly broadened our opportunity to participate in the growth and evolution of the oncology market. But, Tom? Thomas J. Lynch - Bristol-Myers Squibb Company - Executive VP of R&D & Chief Scientific Officer And, Giovanni, just to add to that, I think we've said for quite some time that we've been looking at cell therapy opportunities and looking to complement our immunotherapy approach. And just to remind folks, if you think about the 4 pillars, the way the immune system attacks cancer, we have a very strong PD-1, CTLA-4, IL-2, with our relationship with Nektar, our NKTR-214. And now we add the best-in-class cell therapies approach. And when I've look at the Celgene portfolio, I was incredibly impressed by the work that Rupert and others have done, particularly against BCMA and CD19. These really are transformative products. S. J. Rupert Vessey - Celgene Corporation - President of Research & Early Development Yes, Tom, thanks. Geoff, it's Rupert here. I agree. I mean, one of the great value drivers here will be the combinatorial opportunities that Tom just alluded to. I think the other thing is to look at the portfolio. So, of course, we're well ahead in BCMA, CAR T. As you know, we've just finished enrolling

8 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A

Call the pivotal trial for that program. JCAR017 liso-cell continues to have a best-in-class profile, and you're familiar with the plan for moving that forward. And then I'll just add that something I always say when I'm asked about the cellular therapy platform. First of all, we've now treated more people with cell therapies than anybody else. We have a huge data set, over 700 people treated. The insights that we are gaining from that into optimization of next-generation cellular therapies is not to be underestimated. And we should also think of cellular therapies as an emerging modality rather in the way that antibodies were 20 or 30 years ago, and they take time to optimize, but I can absolutely assure you that there are next-generation candidates coming forward. There are process changes and improvements and bolt-on technologies that I think will continue to open up this field in a really exciting way for the new company.

Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO

Yes. And let me just add from a commercial perspective that we're incredibly excited about not only the platform for CAR T, generally, but also the specific cellular therapies from Celgene. Obviously, you all know this is a challenging space from a commercial standpoint, but as we think about some of these are going to be critical for success, there are probably a few things I would highlight. First, you need to have a differentiated profile. Second, access and the access environment is going to have to change in a positive direction. We're going to have to expand the pool of eligible patients who are considered for these therapies. And importantly, we're going to have to ensure that the patient and physician experiences are as good as they can be with these agents. As I think about each of those, as has already been suggested, we have a real opportunity to have differentiated agents here. You can't lump all of these CAR Ts together, they're very different in terms of their biological make up. If you've seen one cell -- one CAR T, you've seen one CAR T. And when we look at the data from both liso-cel and BB21, we see a differentiated profile. Liso-cel responses are a lot better than those you've seen with this CAR T and Kymriah, with generally less severe AEs. And with bb21 -- bb2121, we think there's a great opportunity to be first to market with BCMA CAR T and have deeper responses in other BCMA modalities, at least based on what we've seen so far. Obviously, the access environment has been challenging. There have been some positive changes of late, we need to see that continue. I will say that this is an area we have deep access experience that we can bring to the table and, hopefully, help shape that in a positive direction. And if we do that along with the differentiated profile, we think you will see an expanded pool of patients who can benefit from these agents. And then the last thing I would highlight is that this is an area where I think the combined company really does bring a lot of core capabilities. I've talked about the deep expertise we bring from an access standpoint. I would just highlight the Celgene leadership and legacy in hematology as being critically important here. So as I sum all of that up, I think I feel really good about the commercial opportunity there.

Operator We will go to Tim Anderson from Wolfe Research. Timothy Minton Anderson - Wolfe Research, LLC - MD of Equity Research

A few questions. So Celgene, you guys are talking about it being a great company and there are certainly some interesting near-term assets. But the P/E multiple on Celgene on 2020 earnings is 6x, so it's the lowest multiple stock in the innovative biopharma space, which speaks to, I think, investor concerns about Revlimid. So in this transaction, you're not giving any long-term guidance, all you've made is a comment about, I think, thinking The Street is mis-modeling Revlimid LOE, so I'm hoping you can address that in a little more detail what do you think is being mis-modeled exactly? And kind of related to this topic, another debate that's going to arise is your confidence in Opdivo, which is your lead asset. There's been a lot of controversy given some of the readouts. There's uncertainty on where the product stands in first line lung, and you've got trials coming up that are going to help answer that question. You've only talked about Opdivo in 2019, saying it's going to grow, but you haven't given any commentary past 2019. So maybe as part of that first answer, you can also talk about your confidence about the growth trajectory of Opdivo beyond 2019.

Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO

Thank you, Tim. Let me just cover the different elements of the question you asked. So first of all, let me start with Opdivo, I think that's really important. As I said, we feel really good about the momentum with Opdivo coming out of 2018. We've described Opdivo as a growing brand in

9 THOMSON REUTERS STREETEVENTS | www.streetevents.com
| Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call 2019. There are over 20 registrational studies ongoing, and we are very excited about the potential for growth of Opdivo going forward. The commitment to Opdivo, obviously, as our key franchise, remains as strong as it's always been. And actually, the strength of our current position is one of the reasons why we feel good about doing this transaction now. With respect to your questions about Revlimid, as I've said in my remarks, we have, as you can imagine, done a lot of due diligence on this. We feel good about what we've seen. And we've presented in my remarks the slide that Mark presents -- presented at ASH, which describes the current status of the Revlimid IP. I've also said, we've obviously looked at a number of different scenarios. Our scenario with respect to the valuation is somewhat more conservative to the one that is reflected in consensus. But we've looked at different scenarios, and we feel good about the valuation under the scenarios we've looked at. Ultimately, while Revlimid is important, this is an important deal with respect to the future growth of the company. The value drivers that we have emphasized are the 6 upcoming launches of the combined company, which are near-term growth opportunities. And then following that, the synergies, we are confident we are going to be able to deliver. And lastly, and importantly, the breadth and depth of the early- and mid-stage pipeline for long-term growth. So that's where we are, and I am confident that under the scenarios we have looked at, this is a great deal for BMS shareholders from a value perspective. Operator We'll take our next question from Alex Arfaei with BMO Capital Markets. Alex Arfaei - BMO Capital Markets Equity Research - Pharmaceuticals Analyst Giovanni, just wondering if you could clarify -- just build a little bit more on your recent answer. You mentioned you've been evaluating this deal for some time. We're just trying to figure out what strategic priorities drove the transaction. Was it the need to diversify from I/O, boost the pipeline? And to what extent was this opportunistic given Celgene's valuation? I'm just trying to figure out, I guess, if you could rank those items in terms of importance for you. Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Well, I think, Alex, all of those things are important, in fact, because I believe that this deal diversifies our current commercial franchises, brings strength to all of them. We strengthened the oncology solid tumor presence we have with a leadership position in hematology, so we diversified the in-line business. Importantly, we strengthened the number of Phase III assets in the company, and we now have 6 near-term launch opportunities. And again, I stress the word near-term because a number of those that are imminent files, they are going to be submitted to regulatory authorities. So this is not a strategic priority that will deliver in the long term, there are concrete short-term growth opportunities that this deal will deliver to Bristol-Myers Squibb. The synergies are important and the long-term sustainability of the growth is important. When you look at the combined company, I believe there is value to be created immediately in the medium term and in the long term. And as I mentioned before, I think about Revlimid as a really important product. I think about Revlimid as the foundation based on which we can maintain a leadership presence in hematology. But this deal is not about Revlimid, this deal is about the short-term launches, the medium- and the long-term optionality of the pipeline. And in terms of the timing, I believe it is always a combination of multiple factors. As I said, we've been discussing this for some time at the company because of the natural fit of the 2 company -- 2 companies. I think this is the right time. I believe the value is right to deliver value to BMS shareholders. And the participation of Celgene shareholder in the new company will do that for Celgene shareholders as well. I personally also believe that we are entering a time of continued evolution of market dynamics from a payer perspective. And I believe that we have a history at Bristol-Myers Squibb to our strategy of transforming ahead of market changes. And I think that, again, we are gaining the scale, the critical mass, the level of diversification needed in order to succeed in tomorrow's market, ahead of many of those trends playing out, and I think it is the right time. Operator We'll take our next question from Seamus Fernandez with Guggenheim. 10 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals So, really, I guess, the big question is, given the timing I think folks asked about this already, but you do have several important positions in lung cancer, trials in lung cancer, to read out in the short term. Can you just give us your view of the go-forward contribution of lung cancer? You guys have talked a lot about the sustained position in second line. But, I guess, we're all wondering how visibility is at this point on your position or potential position globally in first-line lung cancer. And just as a follow-up question to your last comment, Giovanni, about changing markets and potential transforming markets. Can you just help us understand where your area of greatest concern and confidence is in the current volatile landscape? Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, Seamus. So let me just say at very high level from the perspective of lung cancer. As you know, we have a very broad program, there are a number of readouts over the next period. They remain clearly the focus for our organization. If you think about the combined company, I would envision the oncology solid tumor organization of the new company to beat the current Bristol-Myers Squibb organization. And as a result of that, I don't expect us to have any disruption with respect to our ability to execute there. And nothing has changed with respect to how we think about our ability to sustain a leadership position in second-line and the optionality that the broad first-line program provides to us. With respect -- what I would add is that this is a large transaction, of course. We are creating a leading company. But one of the things that I feel really good about is that the new company continues to be really focused. The number of therapeutic areas, the area of science, it's extraordinary how 2 large companies can come together and remain as focused as the 2 companies were before the transaction. So I feel really good about that. With respect to uncertainty in the marketplace, I guess, what I can say, as you know, it's very early with respect to thinking about how policy may evolve in the U.S. But I actually feel good about having 9 assets with over \$1 billion in sales, reimbursement modalities that go from Part B to Part D cell therapy, evolving and very much going in the right direction. I believe breadth is important. And I do believe that depth of presence as leaders in the therapeutic areas in which you talk to payers will be increasingly important. And critical mass, I've always described critical mass as important in highly managed markets and areas. And as the leading oncology company, which is what we are creating today, our competitive positions, including with payers, improves no matter what some of the details or policy evolution will be. Operator Our next question comes from Steve Scala with Cowen. Stephen Michael Scala - Cowen and Company, LLC, Research Division - MD and Senior Research Analyst A lingering concern with Bristol is visibility on the longer-term outlook, given competition in I/O and patent expirations on both Opdivo and Elicuisin the second half of the next decade. It's not clear how buying Celgene increases visibility, particularly given the patent issue with Revlimid, which even in the best case will go lose its protection in a similar time period. Now I appreciate there are many new product launches, but the \$15 billion you are saying they could contribute is less than the likely Opdivo peak sales forecast, so lots of uncertainty here. In the past, in times of great uncertainty, Bristol has provided floor EPS guidance in an out year. 2022 EPS consensus for Bristol is \$5.33, so I wonder if you'd be willing to say that, that is now the floor or perhaps it's a reasonable number. And related to all this, are there any likely or necessary divestitures upon completion of the deal? Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, Steve. So let me just say a couple of things. With respect to the comments you had on losses of exclusivity and long-term sustainability of our growth, I believe that, this morning, we provided you with the first really good insight about the optionality that exists in the pipeline. We see significant opportunity from 6 upcoming launches for many of the products that will be potentially launched in the next 12 to 24 months. The launch will be the first of a number of potential follow-up indications that broaden the opportunities for these products. We see significant opportunity coming from the mid- and early-stage pipeline. We've highlighted some of the products already in the deck that we believe are likely to be the next areas of focus for the company to think about mid- and long-term growth. And of course on the sort of foundation of all of that, 11 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call there is significant opportunity for growth with Eliquis and Opdivo. We have not discussed Eliquis today, but just -- let me just remind you with Opdivo that a number of the 20 registrational opportunities I discussed will be in the adjuvant setting, which is a totally new field for us. So when I think about the short, the medium and the long term, I think about great optionality for growth. In the medium and in the long term, the company will also continue to focus on business development as a really important strategy, but we have significantly strengthened our outlook through this potential combination. One of the things, to answer your second question, so is we're not providing long-term guidance at this point, but we feel really good about the growth prospects of the company. My perspective is that the businesses are complementary and there are no major overlaps that I am concerned about. You see and you know that we just divested our consumer medicines business in France, that was an important step to continue to focus our portfolio. But overall, I would say, the complementarity of the portfolio from a modality perspective, therapeutic area perspective and timing perspective makes this combination quite powerful. Operator Our next question is from Jason Gerberry with Bank of America. Jason Matthew Gerberry - BofA Merrill Lynch, Research Division - MD in US Equity Research Just wanted to come back and just follow-up a little bit around the comments about conservatism, your -- Bristol's conservatism around the Revlimid assumptions versus where consensus is modeling in that. Is that something that you differ as it pertains to this sort of post-2026 dynamic and more of a true cliff -- or more of a true cliff even in the 2024 to 2025 limited quantity period of time. I'm just curious if your difference is really sort of in the nature of the cliff or in the ramp -- the ramp up of Revlimid sales leading up to the entry of the first generic. Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO No. What I would say, Jason, is that we -- as I said, we have looked at this very carefully. Mark presented a really good updated at ASH months ago. I think we are very comfortable with the way Celgene has been looking at the Revlimid and the Revlimid IP issue. I think you would expect us to model a number of scenarios. As I said before, this deal is really all about the launches, the pipeline, the value of the synergies. But clearly, the financial value of Revlimid is really important, and as a result of that, we have looked at that very carefully. Operator Our next question is from David Risinger with Morgan Stanley. David Reed Risinger - Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst Congrats on the transaction. I am curious and want to hear a little more color about your assessment of Celgene's pipeline. You've obviously commented on it already, but it would be helpful if you could dig in a little deeper to help us understand what you think the consensus currently under-appreciates about Celgene's pipeline. Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you. Tom, why don't you take that? Thomas J. Lynch - Bristol-Myers Squibb Company - Executive VP of R&D & Chief Scientific Officer I'll start and then ask Rupert for his comments as well. So Giovanni said at the very beginning, one of the key points of the way we look at this is that you're bringing together 2 very large, very successful companies, which really have complementary but very well-aligned pipelines, in that 12 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A

Call the areas that we're looking at, exploring the immune system, understanding what underlies both the immune reaction to cancer and immunosystem (inaudible) in autoimmune disease. These are fundamental similarities between 2 companies, and I think that gives us a remarkable opportunity for a complementary approach in this setting. There are a couple of things. I mean, when I look at Celgene, I look at a company that has completely transformed the way patients with myeloma are treated. Very much the way we have completely transformed the way patients with melanoma and renal cell cancer have been treated. When you think of how both of these companies have made an enormous contribution to human health over the past decade, they're very similar in those 2 respects. And what I'm struck by when I look at Celgene is how that path continues as we move forward. So yes, the image are extremely important, but when you look at what's behind the image, the understanding of the science of what drives the response to Revlimid and Pomalyst, understanding that protein homeostasis within the cell is really a crucial part of how we get our antitumor responses, with the CELMoDs which are being developed by Celgene, have extreme potential, not just in diseases, like myeloma or other hematologic malignancies, but potentially even having applicability into solid tumors. When one looks at the areas of cellular therapy, you are looking at the finest company in the world in terms of their cellular therapy abilities, and so that again also adds to this. And then, finally, in immuno science, you look at a drug like ozanimod and you look at the potential of ozanimod as -- and our drug TYK2 as we look forward, to really expand the ability of oral agents to make a big difference in patients with autoimmune disease. We have not been in the MS space before, but in multiple sclerosis, the ozanimod offers great potential. And then both ozanimod and TYK2 offer great potential for patients with inflammatory bowel disease down the road as well. And then when one looks deeper in the pipeline, you see that, together, we have about 60 agents, which are in development, which we believe have the potential to offer value in the late phase of this, in the 2026 to 2029 framework. So you see alignment around strategy, you see alignment around the commitment to translational science and fundamental biology. And again, I think this has characterized both companies as we move forward. Rupert? S. J. Rupert Vessey - Celgene Corporation - President of Research & Early Development Yes. Tom, I think you've covered it extremely well. So, I mean, clearly, we talked a lot about the 5 near-term products that Celgene is bringing to the table in this transaction. They're visible, most of you know, a lot about those and they're real and they're on their path. From a Celgene point of view, looking further back, we have a whole campaign around BCMA for the treatment of myeloma. And we're the leaders in this, we've got the leading cellular therapy. We have a differentiated bispecific antibody, which is moving along very nicely in the clinic. We also have an antibody drug conjugate, which is just about to be filed as an IND. So we've got all approaches to that extremely highly validated target, which positions that part of the pipeline extremely well. Tom mentioned the cellular therapies and I talked about those earlier, so I won't go back over those comments. But the other piece that I think is really worth highlighting is the protein homeostasis platform. We did a deep dive on this a couple of years ago for our investor community. That information is available, should you like to go back and look at that. And things have advanced dramatically since then. Celgene is the leader in understanding how to use the cerebellum pathway to degrade critical target proteins. And we've been at the forefront of understanding the mechanism of action of these drugs. We have several cerebellum-modulating drugs that are now in the clinic. They're for myeloma, they're for AML, they're for lymphoma. They're advancing extremely well. And behind that, there is a significant effort to move this into solid tumors. We're also able to leverage this technology for other strategies of protein degradation, and what this does for you is open up the opportunity to go after drug targets that are completely inaccessible to standard modalities, such as conventional small molecule chemistry or biologics. I think this part of the portfolio will be extremely complementary to what BMS has in the pipeline. And I think you can look forward to a lot of extremely important combinatorial studies from the extensive pipeline that we now have. Operator We have a question from John Boris with SunTrust. John Thomas Boris - SunTrust Robinson Humphrey, Inc., Research Division - MD Congratulations on the deal. The first just has to do with a lot of e-mails we've gotten on the contingent value rights for the 3 assets. In fact, one of the assets with blue is the bb2121 is obviously in a partnership. Those that are partnered to -- is there any impact on that partnership from the transaction? And then on those 3 drugs, can you talk about probability of success, some of the clinical data filing timelines and approval? Can you give some specific -- more specific information on that? And then secondly, on the breakup fee, is there any breakup fee should you decide not to go through with the transaction? And then lastly, did Celgene entertain any other competitive bidders? 13 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or

similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO So Charlie, do you want to start? Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO Yes. So for bb2121, and Mark is here and can confirm that there is no issue with having the CVR and bb2121. Mark J. Alles - Celgene Corporation - Chairman & CEO No. And I'd only add, Charlie -- exactly right. I'd only add that the CVR actually contemplates the importance to both companies of bb2121 and its best-in-class first-in-class status. Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO Yes. And in regard to the breakup fee, there will be a breakup fee, that's customary and sort of standard in deals of this transaction. Mark J. Alles - Celgene Corporation - Chairman & CEO With respect to the process, we're very confident that this transaction with BMS is the best alternative available to Celgene. It delivers immediate substantial value to our shareholders. It allows them to participate, as you've heard from Giovanni and Charlie this morning, in the opportunity for long-term sustainable growth by the combination. So we feel very, very good that this is the right transaction at the right time for Celgene. Operator Our final question will be from Geoffrey Porges with Leerink Partners. Geoffrey Craig Porges - Leerink Partners LLC, Research Division - Director of Therapeutics Research, MD & Senior Biotechnology Analyst A follow up on the question about breakup fees. Is there a collar for the Bristol share price associated with the transaction? We are in volatile markets and just want to know whether there is any limit to Celgene's owners or recommendation of Celgene's board. And then just on the pipeline, are there any obvious combination strategies that you have seen, Tom or Rupert, when you've looked over the portfolios in terms of parts that you may codevelop or study in combination that you may not have done previously? Charles A. Bancroft - Bristol-Myers Squibb Company - Executive VP of Global Business Operations & CFO Yes. So Geoffrey, just in context of the deal, there is no collar. It's a straight one-to-one exchange. Thomas J. Lynch - Bristol-Myers Squibb Company - Executive VP of R&D & Chief Scientific Officer Regarding combinations, I think that Rupert alluded to this earlier, I think that many people are interested in trying to unlock the potential of what cell therapies would do when used in combination with checkpoint inhibitors. So PD-1 drugs with cell therapies is an area that I think would make a lot of sense, both in terms of thinking about how we approach diseases like hematologic malignancies and melanoma and renal cell, but also thinking about how this could unlock the potential of immunologic approaches to "cold" tumors. So I think there are a lot of potential opportunities in that cancer space as well. Then I think the other point to think about in terms of combinations is how do we approach autoimmune disease.

I 14 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.

Client Id: 77 JANUARY 03, 2019 / 1:00PM, CELG - Bristol-Myers Squibb Co to Acquire Celgene Corp M&A Call think it's really important for people to recognize that there remains remarkable unmet need for patients who have inflammatory bowel diseases, both UC and Crohn's, while a number of agents have definitely changed the way these diseases are treated, there are still patients who are suffering from these diseases. And I look at the Celgene pipeline or to our pipeline, and I think that we have the opportunity there for some combinatorial activity that could actually make a difference in treating these diseases, long term. Giovanni Caforio - Bristol-Myers Squibb Company - Chairman of the Board & CEO Thank you, Tom, and thanks, everyone. As we close, let me just say I thank you for participating in this call. This is a really historic day for both companies. I am excited at Bristol-Myers Squibb that we are creating a premier innovation biopharma company. We have discussed on the call the opportunities in the short term for creation of value for our shareholders, medium and long term with respect to the sustainability of our growth, and the value that this transaction generates. I'm really excited about this. Obviously, our team remains available for all of you to continue to answer questions. I want to thank you for being on the call, and wish you Happy New Year. John E. Elicker - Bristol-Myers Squibb Company - SVP of Corporate Affairs & IR That concludes the call, Nicole. Thank you. Operator Thank you. Once again, ladies and gentlemen, that does conclude today's conference. We appreciate your participation today. You may now disconnect. **DISCLAIMER** Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes. In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized. **THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.** ©2019, Thomson Reuters. All Rights Reserved. 12250871-2019-01-03T15:39:48.683 15 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us ©2019 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies.
